Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio

Zimmermann, Sebastian; Aghai, Fatemeh; Schilling, Bastian; Kraus, Sabrina; Grigoleit, Götz Ulrich; Kalogirou, Charis; Goebeler, Maria-Elisabeth; Jung, Pius; Pelzer, Theo; Klinker, Hartwig; Isberner, Nora; Oliver, Susan

doi:10.1016/j.jpba.2022.114623

Cited by 19 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the sample preparation of dried plasma spots (DPS) for the measurement of bosutinib, dasatinib, ibrutinib, imatinib, nilotinib and ponatinib consisted of a liquid extraction step followed by solid-phase extraction and subsequent drying ( 43 ). In two VAMS-based methods, VAMS samples were pre-wetted with an aqueous solution prior to the addition of an organic solvent for extraction ( 35 , 46 ). Overall, a robust extraction procedure is key to the reliability of a method using dried blood microsamples.…”

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

“…Specificity is achieved by separation of the compounds on LC columns and detection in multiple reaction monitoring (MRM) mode. Several multi-TKI LC-MS/MS methods have been developed ( 35 , 41 , 43 , 46 ), offering the advantage that one dedicated method can be applied for a variety of analytes (and, hence patient samples), which is especially relevant in routine clinical settings. Known disadvantages of LC-MS/MS are the high investment and maintenance cost, the high technical expertise that is required and the need for time-consuming sample preparation, which is typically more laborious for dried microsamples, when compared with plasma samples.…”

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

“…Several authors investigated the stability of TKIs in dried microsamples stored at higher temperatures, to simulate extreme temperature conditions that could be encountered during transportation to the laboratory via regular mail (e.g. in a postbox fully exposed to the sun during summer): gefitinib was stable for 24h at 40°C ( 40 ), imatinib and nilotinib were stable for at least three days at 40°C (this was not the case for dasatinib) ( 41 ), imatinib for 36 days at 43°C ( 36 ) and most TKIs of two different TKI panels in VAMS for at least 2 days at 60°C ( 35 , 46 ). It should be noted that not in all instances where instability was reported, the authors verified whether extractability wasn’t affected, hence resulting in apparent instability ( 57 ).…”

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

“…This only results in automation and time saving for the preparation of the VAMS samples themselves, with extraction and chromatographic analysis still requiring manual processes ( 72 ). To date, two groups have investigated the measurement of TKIs using VAMS, establishing multi-analyte methods for the simultaneous quantification of eight ( 35 ) or ten TKIs ( 46 ). Other volumetric microsampling devices avoiding the Hct and inhomogeneity bias include the HemaPEN (Trajan, Melbourne, Australia), Capitainer qDBS (Capitainer, Solna, Sweden) and HemaXis DB 10 (HemaXis, Gland, Switzerland) device ( 66 ).…”

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

“…Moreover, one should know whether the Hct level of the sample lies within the covered Hct range – the above-mentioned Hct prediction strategies allow to derive this information. In the different published TKI methods the standards were prepared in blank blood with a Hct of 0.40 ( 35 ), 0.42 ( 41 ), 0.35 ( 36 ), 0.44 ( 45 ), 0.40 ( 37 ), 0.38 ( 39 ) or 0.45 ( 46 ).…”

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

See 4 more Smart Citations

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples

et al. 2022

View full text Add to dashboard Cite

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs) is not yet performed routinely in the standard care of oncology patients, although it offers a high potential to improve treatment outcome and minimize toxicity. TKIs are perfect candidates for TDM as they show a relatively small therapeutic window, a wide inter-patient variability in pharmacokinetics and a correlation between drug concentration and effect. Moreover, most of the available TKIs are susceptible to various drug-drug interactions and medication adherence can be checked by performing TDM. Plasma, obtained via traditional venous blood sampling, is the standard matrix for TDM of TKIs. However, the use of plasma poses some challenges related to sampling and stability. The use of dried blood microsamples can overcome these limitations. Collection of samples via finger-prick is minimally invasive and considered convenient and simple, enabling sampling by the patients themselves in their home-setting. The collection of small sample volumes is especially relevant for use in pediatric populations or in pharmacokinetic studies. Additionally, working with dried matrices improves compound stability, resulting in convenient and cost-effective transport and storage of the samples. In this review we focus on the different dried blood microsample-based methods that were used for the quantification of TKIs. Despite the many advantages associated with dried blood microsampling, quantitative analyses are also associated with some specific difficulties. Different methodological aspects of microsampling-based methods are discussed and applied to TDM of TKIs. We focus on sample preparation, analytics, internal standards, dilution of samples, external quality controls, dried blood spot specific validation parameters, stability and blood-to-plasma conversion methods. The various impacts of deviating hematocrit values on quantitative results are discussed in a separate section as this is a key issue and undoubtedly the most widely discussed issue in the analysis of dried blood microsamples. Lastly, the applicability and feasibility of performing TDM using microsamples in a real-life home-sampling context is discussed.

show abstract

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

Section: Methodological Aspects Of Dried Blood Microsample Methods Fo...mentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples

et al. 2022

View full text Add to dashboard Cite

show abstract

Blood microsampling technologies: Innovations and applications in 2022

Thangavelu

Wouters

Kindt

et al. 2023

Analytical Science Advances

View full text Add to dashboard Cite

With the development of highly sensitive bioanalytical techniques, the volume of samples necessary for accurate analysis has reduced. Microsampling, the process of obtaining small amounts of blood, has thus gained popularity as it offers minimal‐invasiveness, reduced logistical costs and biohazard risks while simultaneously showing increased sample stability and a potential for the decentralization of the approach and at‐home self‐sampling. Although the benefits of microsampling have been recognised, its adoption in clinical practice has been slow. Several microsampling technologies and devices are currently available and employed in research studies for various biomedical applications. This review provides an overview of the state‐of‐the‐art in microsampling technology with a focus on the latest developments and advancements in the field of microsampling. Research published in the year 2022, including studies (i) developing strategies for the quantitation of analytes in microsamples and (ii) bridging and comparing the interchangeability between matrices and choice of technology for a given application, is reviewed to assess the advantages, challenges and limitations of the current state of microsampling. Successful implementation of microsampling in routine clinical care requires continued efforts for standardization and harmonization. Microsampling has been shown to facilitate data‐rich studies and a patient‐centric approach to healthcare and is foreseen to play a central role in the future digital revolution of healthcare through continuous monitoring to improve the quality of life.

show abstract

Targeted and untargeted metabolomics and lipidomics in dried blood microsampling: Recent applications and perspectives

Couacault,

Avella,

Londoño‐Osorio

et al. 2024

Analytical Science Advances

View full text Add to dashboard Cite

Blood microsampling (BµS) offers an alternative to conventional methods that use plasma or serum for profiling human health, being minimally invasive and cost effective, especially beneficial for vulnerable populations. We present a non‐systematic review that offers a synopsis of the analytical methods, applications and perspectives related to dry blood microsampling in targeted and untargeted metabolomics and lipidomics research in the years 2022 and 2023. BµS shows potential in neonatal and paediatric studies, therapeutic drug monitoring, metabolite screening, biomarker research, sports supervision, clinical disorders studies and forensic toxicology. Notably, dried blood spots and volumetric absorptive microsampling options have been more extensively studied than other volumetric technologies. Therefore, we suggest that a further investigation and application of the volumetric technologies will contribute to the use of BµS as an alternative to conventional methods. Conversely, we support the idea that harmonisation of the analytical methods when using BµS would have a positive impact on its implementation.

show abstract

Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio

Cited by 19 publications

References 30 publications

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples

Blood microsampling technologies: Innovations and applications in 2022

Targeted and untargeted metabolomics and lipidomics in dried blood microsampling: Recent applications and perspectives

Contact Info

Product

Resources

About